tite.mams: Function to design multi-arm multi-stage studies with...

In MAMS: Designing Multi-Arm Multi-Stage Studies

Function to design multi-arm multi-stage studies with time-to-event endpoints

Description

The function determines (approximately) the boundaries of a multi-arm multi-stage study with time-to-event endpoints for a given boundary shape and finds the required number of events.

Usage

tite.mams(hr=1.5, hr0=1.1, K=4, J=2, alpha=0.05, power=0.9,
           r=1:2, r0=1:2, ushape="obf", lshape="fixed", ufix=NULL,
           lfix=0, nstart=1, nstop=NULL, sample.size=TRUE, N=20,
           parallel=TRUE, print=TRUE)

Arguments

hr	Interesting treatment effect on the scale of hazard ratios (default=2).
hr0	Uninteresting treatment effect on the scale of hazard ratios (default=1.2).
K	Number of experimental treatments (default=4).
J	Number of stages (default=2).
alpha	One-sided familywise error rate (default=0.05).
power	Desired power (default=0.9).
r	Vector of allocation ratios (default=1:2).
r0	Vector ratio on control (default=1:2).
ushape	Shape of upper boundary. Either a function specifying the shape or one of "pocock", "obf" (the default), "triangular" and "fixed".
lshape	Shape of lower boundary. Either a function specifying the shape or one of "pocock", "obf", "triangular" and "fixed" (the default).
ufix	Fixed upper boundary (default=NULL). Only used if shape="fixed".
lfix	Fixed lower boundary (default=0). Only used if shape="fixed".
nstart	Starting point for finding the sample size (default=1).
nstop	Stopping point for finding the sample size (default=NULL).
sample.size	Logical if sample size should be found as well (default=TRUE).
N	Number of quadrature points per dimension in the outer integral (default=20).
parallel	if TRUE (default), allows parallelisation of the computation via a user-defined strategy specified by means of the function future::plan(). If not set differently, the default strategy is sequential, which corresponds to a computation without parallelisation.
print	if TRUE (default), indicate at which stage the computation is.

Details

This function finds the (approximate) boundaries and sample size of a multi-arm multi-stage study with time-to-event endpoints with K active treatments plus control in which all promising treatments are continued at interim analyses as described in Magirr et al (2012). It is a wrapper around the basic mams function to facilitate its use with time-to-event endpoints, following ideas of Jaki & Magirr (2013). Note that the sample size is calculated as the required number of events, from which the total sample size can be estimated (e.g., Whitehead 2001). See ?mams for further details on the basic methodology.

Value

An object of the class MAMS containing the following components:

l	Lower boundary.
u	Upper boundary.
n	Sample size on control in stage 1.
N	Maximum total sample size.
K	Number of experimental treatments.
J	Number of stages in the trial.
alpha	Familywise error rate.
alpha.star	Cumulative familywise error rate spent by each analysis.
power	Power under least favorable configuration.
rMat	Matrix of allocation ratios. First row corresponds to control while subsequent rows are for the experimental treatments.

Author(s)

Philip Pallmann, Dominic Magirr

References

Jaki T. and Magirr D. (2013), Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments, Statistics in Medicine, 32(7), 1150-1163. Link: \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1002/sim.5669")}

Jaki T., Pallmann P. and Magirr D. (2019), The R Package MAMS for Designing Multi-Arm Multi-Stage Clinical Trials, Journal of Statistical Software, 88(4), 1-25. Link: \Sexpr[results=rd]{tools:::Rd_expr_doi("10.18637/jss.v088.i04")}

Magirr D., Jaki T. and Whitehead J. (2012), A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection, Biometrika, 99(2), 494-501. Link: \Sexpr[results=rd]{tools:::Rd_expr_doi("10.1093/biomet/ass002")}

Whitehead J. (2001), Predicting the duration of sequential survival studies, Drug Information Journal, 35(4), 1387-1400.

See Also

print.MAMS, summary.MAMS, plot.MAMS, mams, MAMS.

Examples

## An example 2-stage design with triangular efficacy and futility boundaries
tite.mams(hr=2, hr0=1.5, K=3, J=2, alpha=0.05, power=0.9,
          r=1:2, r0=1:2, ushape="triangular", lshape="triangular")

MAMS documentation built on April 18, 2023, 5:08 p.m.